In a recent op-ed published by Marijuana Moment, Joshua S. Bauchner, Chair of Mandelbaum Barrett PC’s Cannabis, Hemp, and Psychedelics Practice Group, and Marky Suazo, Counsel in the Group, examine a critical but often overlooked consequence of federal marijuana rescheduling: the Drug Enforcement Administration’s growing role as a regulator of the cannabis industry.
The article explains that while the Department of Justice’s decision to move state-licensed medical marijuana from Schedule I to Schedule III has generated significant attention for its potential tax and financial benefits, it also signals increased federal oversight of cannabis businesses. As operators seek the legitimacy that comes with federal reform, they may now face new compliance obligations through DEA registration, reporting requirements, and enhanced scrutiny of ownership structures, inventory controls, and operational procedures.
Josh and Marky note that cannabis companies have historically operated under state regulatory frameworks, with limited involvement from federal agencies. That landscape is rapidly changing. As the federal government develops a regulatory framework for Schedule III medical cannabis businesses, operators are being asked to make strategic business decisions amid ongoing uncertainty surrounding registration requirements, compliance standards, and the treatment of businesses that participate in both medical and adult-use markets.
The authors emphasize that federal reform is already underway and that cannabis operators cannot afford to take a wait-and-see approach. Businesses should proactively evaluate their governance practices, compliance programs, recordkeeping systems, and ownership structures to prepare for potential federal oversight.
The article closes by urging the DEA to provide clearer guidance on registration requirements, inspection standards, and how federal oversight will work alongside existing state regulatory programs. Until that framework is established, cannabis businesses will be left making important operational and investment decisions without a clear understanding of the federal rules that may apply.
As marijuana rescheduling moves through the federal process, Josh and Marky offer a practical perspective on what increased DEA involvement could mean for cannabis operators.
Read the full article here.